(Q34631801)

3 August 2017

1 reference

title

Novel radiolabeled antibody conjugates (English)

1 reference

3 August 2017

1 reference

Goldenberg DM

1

1 reference

3 August 2017

Sharkey RM

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

26

1 reference

3 August 2017

issue

25

1 reference

3 August 2017

page(s)

3734-3744

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210373

3 August 2017

exact match

0 references

cites work

Colorectal carcinoma: detection with indium-111 anticarcinoembryonic-antigen monoclonal antibody ZCE-025.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Pharmacokinetics and biodistribution of genetically engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Engineering novel binding proteins from nonimmunoglobulin domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

The radioisotope contributes significantly to the activity of radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Nuclear medicine studies of the prostate, testes, and bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

The progress and promise of molecular imaging probes in oncologic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Tailoring antibodies for radionuclide delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Radioimmunotherapy of brain tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Advances in radioimmunotherapy in the age of molecular engineering and pretargeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Systemic targeted radionuclide therapy: potential new areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Antibodies against metal chelates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Studies directed toward the use of antibodies as carriers of radioactivity for therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Clinical radioimmunodetection of cancer with radioactive antibodies to human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Biologic properties of a CH2 domain-deleted recombinant immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Radioimmunotherapy for B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210373

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210373

1 reference

Dimensions Publication ID

3 August 2017

1014120431

0 references

1 reference